Navigation Links
Amicus Therapeutics Commences Phase 3 Trial Evaluating Amigal(TM) for the Treatment of Fabry Disease
Date:6/22/2009

l.

European Phase 3 Registration Trial Update

Amicus and its partner, Shire Human Genetic Therapies, Inc. (Shire HGT), have completed a series of discussions with the European Medicines Agency (EMEA). Based on feedback from the EMEA, the Companies expect a separate clinical study will be required for Amigal registration in Europe.

The EMEA has recommended a registration trial evaluating the safety and efficacy of Amigal in males and females with Fabry disease as compared to enzyme replacement therapy (ERT). The Agency agrees that the trial may enroll subjects currently receiving ERT. The recommended primary endpoint is renal function as measured by glomerular filtration rate (GFR) and the recommended primary analysis is a comparison of outcomes between the Amigal and ERT groups using descriptive statistics.

Amicus and Shire HGT are reviewing the final EMEA feedback and will provide an update regarding plans for registration in Europe in the second half of 2009.

About Amigal

Amigal has undergone clinical testing in a series of Phase 2 studies. Twenty-six male and female subjects were included in these studies and studied initially for either 12 or 24 weeks. Twenty-three of the 26 subjects continue to receive treatment in an ongoing extension study designed to evaluate the long-term safety and efficacy of Amigal. Fifteen of the 23 subjects have been on treatment for at least two years and five subjects have been on treatment for more than three years.

Results from the Phase 2 and the extension study were presented in March 2009 at the American College of Medical Genetics (ACMG) Annual Meeting in Tampa, FL. Specifically, Amicus reported that treatment with Amigal was generally well-tolerated, with no drug-related serious adverse events. The most common adverse events were headache, arthralgia and diarrhea. In s
'/>"/>

SOURCE Amicus Therapeutics
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
2. Amicus Therapeutics Announces Plans to Present Phase 1 Data for AT2220 for Pompe Disease
3. Amicus Therapeutics Announces Positive Results From Two Phase 1 Clinical Studies of AT2220 for Pompe Disease
4. Amicus Therapeutics to Present at the 26th Annual JPMorgan Healthcare Conference
5. Amicus Therapeutics Presents Data from Clinical Ex Vivo Response Study and Phase 1 Studies of AT2220
6. Amicus Therapeutics Begins Phase 2 Clinical Trial of AT2220 in Pompe Disease
7. Amicus Therapeutics Announces Successful Completion of End of Phase 2 Meeting With FDA for Amigal in Fabry Disease
8. Amicus Therapeutics Announces Second Quarter 2008 Financial Results
9. Amicus Therapeutics Announces Positive Progress of Three Lead Clinical Programs and General Outlook for 2009
10. Amicus Therapeutics Suspends Enrollment for Phase 2 Clinical Trial of AT2220 for Pompe Disease
11. Amicus Therapeutics Announces Issuance of New Plicera(TM) Composition of Matter Patent
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 2014 Reportlinker.com announces that a new ... catalogue: Insulin Pump ... http://www.reportlinker.com/p01957812/Insulin-Pump-Market--Forecast-–-Worldwide-Analysis.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Medical_Equipment_and_Supply ... Insulin Pumps are gaining strong acceptance ...
(Date:1/15/2014)... CAMBRIDGE, Mass. , Jan. 15, 2014  Zafgen, ... the unmet needs of severely obese patients, today ... of beloranib, a selective inhibitor of methionine aminopeptidase ... a severe form of genetic obesity.  These results ...
(Date:1/14/2014)... , Jan. 14, 2014 The Brandeis Medical Center, led ... a premier and affordable laser tattoo removal experience with ... Brandeis, focus is in providing high quality cosmetic services with cutting ... " Southern California has seen a ...
Breaking Medicine Technology:Insulin Pump Market & Forecast - Worldwide Analysis 2Insulin Pump Market & Forecast - Worldwide Analysis 3Insulin Pump Market & Forecast - Worldwide Analysis 4Insulin Pump Market & Forecast - Worldwide Analysis 5Insulin Pump Market & Forecast - Worldwide Analysis 6Insulin Pump Market & Forecast - Worldwide Analysis 7Insulin Pump Market & Forecast - Worldwide Analysis 8Insulin Pump Market & Forecast - Worldwide Analysis 9Insulin Pump Market & Forecast - Worldwide Analysis 10Insulin Pump Market & Forecast - Worldwide Analysis 11Insulin Pump Market & Forecast - Worldwide Analysis 12Insulin Pump Market & Forecast - Worldwide Analysis 13Insulin Pump Market & Forecast - Worldwide Analysis 14Insulin Pump Market & Forecast - Worldwide Analysis 15Insulin Pump Market & Forecast - Worldwide Analysis 16Insulin Pump Market & Forecast - Worldwide Analysis 17Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 2Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 4Beverly Hills Physician Features Tattoo Removal with the Astanza Duality Laser, Offers $99 Special 2
... 7, 2011 EntreMed, Inc. (Nasdaq: ENMD ... treatment of cancer, today announced that Selected Value Therapeutics ... an exclusive license to develop and commercialize EntreMed,s Phase ... of its territories.  EntreMed retains development and commercialization rights ...
... June 7, 2011 Topaz Pharmaceuticals Inc., a privately ... Food and Drug Administration (FDA) accepted for filing the ... topical cream as a treatment for head lice infestations ... represents the transition of the Company from the development ...
Cached Medicine Technology:Selected Value Therapeutics Exercises Right to Develop and Commercialize ENMD-2076 in China 2Selected Value Therapeutics Exercises Right to Develop and Commercialize ENMD-2076 in China 3Selected Value Therapeutics Exercises Right to Develop and Commercialize ENMD-2076 in China 4Topaz Pharmaceuticals Announces New Drug Application for the Treatment of Head Lice Accepted by FDA 2Topaz Pharmaceuticals Announces New Drug Application for the Treatment of Head Lice Accepted by FDA 3
(Date:7/10/2014)... the clinical indicators most strongly associated with concussion is ... evidence-based guidelines for concussion diagnosis, prognosis, and treatment, according ... , official journal of the Congress ... Lippincott Williams & Wilkins , a part of ... on analysis of the best available research data, a ...
(Date:7/10/2014)... just as tempting as full-fat equivalents could be ... into how proteins can replace fats without affecting ... the Engineering and Physical Sciences Research Council (EPSRC), ... of Edinburgh has produced modified proteins that easily ... the behaviour of fats during food manufacture. The ...
(Date:7/9/2014)... that sudden, acute episodes of low back pain are ... air pressure, wind direction and precipitation. Findings published in ... the American College of Rheumatology (ACR), indicate that the ... wind speed or wind gusts, but was not clinically ... (WHO) nearly everyone experiences low back pain at some ...
(Date:7/9/2014)... in almost all types of cancer sends the protein ... fuel a tumour,s uncontrolled growth, new research suggests. , ... a molecular trigger responsible for ratcheting up activity of ... makes the building blocks cancer cells need to keep ... called SREBP, controls the flow of messages to the ...
(Date:7/9/2014)... found that fecal transplantation is effective and safe for ... is the result of a study led by Colleen ... Gastrointestinal Medicine at The Women,s Medicine Collaborative. The study ... of print in the American Journal of Gastroenterology ... diff , has increased to epidemic proportions over the ...
Breaking Medicine News(10 mins):Health News:What's a concussion? Review identifies four evidence-based indicators 2Health News:What's a concussion? Review identifies four evidence-based indicators 3Health News:Great tasting low-fat cheeses and cakes could soon be on the menu 2Health News:Low back pain? Don't blame the weather 2Health News:Signal may send cancer's cellular factories into overdrive 2Health News:Women's Medicine Collaborative examines safety of fecal transplant to treat C. difficile 2
... confirms that impotence is a risk factor for heart ... suffering from both cardiovascular disease and erectile dysfunction are ... and death, a new study finds. , Moreover, treatments ... so the German researchers concluded that erectile dysfunction is ...
... ... between the corporate and academic worlds in the medical device industry. , ... (PRWEB) March 15, 2010 -- The First Annual ... Hosted by the Biomedical Engineering Society @ San Jose State University, this event will take ...
... ... at Children,s Memorial Hospital may be able to identify infants at high risk ... 48 hours after birth. The medical device making this possible is called the Pea ... fast, non-invasive mechanism to measure newborn body fat. , ...
... Reno , Salt Lake City , and Denver in May are set to help employers improve hearing conservation efforts and prevent noise-induced hearing loss among their workers. , ... , ... ... ...
... The Greater San Antonio Chamber of Commerce and ... at a luncheon on March 31st who have made ... part of the 2010 Women,s Opportunity Week (WOW), Ford Motor Company ... McClendon ( Texas State Representative, District 120 ), ...
... NEW YORK , March 15 Expectant mothers ... pregnancy experience thanks to the new Prenatal Yoga for Partners ... organic baby and toddler food company. One of the only products ... and founder Shazi Visram and her husband, Joe ...
Cached Medicine News:Health News:Erectile Dysfunction Plus Heart Disease Raises Death Risk 2Health News:Erectile Dysfunction Plus Heart Disease Raises Death Risk 3Health News:First Annual Bay Area Biomedical Device Conference to be Held at San Jose State University 2Health News:First Annual Bay Area Biomedical Device Conference to be Held at San Jose State University 3Health News:Study to Identify Infants at High Risk for Developing Obesity 2Health News:Study to Identify Infants at High Risk for Developing Obesity 3Health News:Free Seminars to Help Employers Prevent Noise-Induced Hearing Loss Among Workers Set for Phoenix, Reno, Salt Lake City, Denver in May 2Health News:Free Seminars to Help Employers Prevent Noise-Induced Hearing Loss Among Workers Set for Phoenix, Reno, Salt Lake City, Denver in May 3Health News:Free Seminars to Help Employers Prevent Noise-Induced Hearing Loss Among Workers Set for Phoenix, Reno, Salt Lake City, Denver in May 4Health News:Free Seminars to Help Employers Prevent Noise-Induced Hearing Loss Among Workers Set for Phoenix, Reno, Salt Lake City, Denver in May 5Health News:Free Seminars to Help Employers Prevent Noise-Induced Hearing Loss Among Workers Set for Phoenix, Reno, Salt Lake City, Denver in May 6Health News:Free Seminars to Help Employers Prevent Noise-Induced Hearing Loss Among Workers Set for Phoenix, Reno, Salt Lake City, Denver in May 7Health News:San Antonio Chamber Honors Women Business, Community Leaders 2Health News:San Antonio Chamber Honors Women Business, Community Leaders 3Health News:San Antonio Chamber Honors Women Business, Community Leaders 4Health News:HAPPYBABY Unveils Partners Prenatal Instructional Yoga DVD 2Health News:HAPPYBABY Unveils Partners Prenatal Instructional Yoga DVD 3Health News:HAPPYBABY Unveils Partners Prenatal Instructional Yoga DVD 4
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: